EP2673265B1 - Formation of n-protected bis-3,6-(4-aminoalkyl) -2,5,diketopiperazine - Google Patents

Formation of n-protected bis-3,6-(4-aminoalkyl) -2,5,diketopiperazine Download PDF

Info

Publication number
EP2673265B1
EP2673265B1 EP12744320.8A EP12744320A EP2673265B1 EP 2673265 B1 EP2673265 B1 EP 2673265B1 EP 12744320 A EP12744320 A EP 12744320A EP 2673265 B1 EP2673265 B1 EP 2673265B1
Authority
EP
European Patent Office
Prior art keywords
water
mixture
diketopiperazine
trifluoroacetyl
lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12744320.8A
Other languages
German (de)
French (fr)
Other versions
EP2673265A2 (en
EP2673265A4 (en
Inventor
John J. FREEMAN
Adrienne STAMPER
Melissa HEITMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161441525P priority Critical
Application filed by Mannkind Corp filed Critical Mannkind Corp
Priority to PCT/US2012/024160 priority patent/WO2012109256A2/en
Publication of EP2673265A2 publication Critical patent/EP2673265A2/en
Publication of EP2673265A4 publication Critical patent/EP2673265A4/en
Application granted granted Critical
Publication of EP2673265B1 publication Critical patent/EP2673265B1/en
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0215Sulfur-containing compounds
    • B01J31/0225Sulfur-containing compounds comprising sulfonic acid groups or the corresponding salts
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0255Phosphorus containing compounds
    • B01J31/0257Phosphorus acids or phosphorus acid esters
    • B01J31/0258Phosphoric acid mono-, di- or triesters ((RO)(R'O)2P=O), i.e. R= C, R'= C, H
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0255Phosphorus containing compounds
    • B01J31/0257Phosphorus acids or phosphorus acid esters
    • B01J31/0259Phosphorus acids or phosphorus acid esters comprising phosphorous acid (-ester) groups ((RO)P(OR')2) or the isomeric phosphonic acid (-ester) groups (R(R'O)2P=O), i.e. R= C, R'= C, H
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions

Description

    TECHNICAL FIELD
  • The present invention relates to compositions for delivering active agents, and particularly biologically active agents. Disclosed embodiments are in the field of chemical synthesis and more particularly are related to improved synthetic methods for the preparation and purification of 3,6-di-substituted-2,5-diketopiperazines.
  • BACKGROUND
  • Drug delivery is a persistent problem in the administration of active agents to patients. Conventional means for delivering active agents are often severely limited by biological, chemical, and physical barriers. Typically, these barriers are imposed by the environment through which delivery occurs, the environment of the target for delivery, or the target itself.
  • Biologically active agents are particularly vulnerable to such barriers. For example, in the delivery of pharmacological and therapeutic agents to humans, barriers are imposed by the body. Examples of physical barriers are the skin and various organ membranes that must be traversed before reaching a target. Chemical barriers include, but are not limited to, pH variations, lipid bi-layers, and degrading enzymes.
  • These barriers are of particular significance in the design of oral delivery systems. Oral delivery of many biologically active agents would be the route of choice for administration to animals if not for biological, chemical, and physical barriers such as varying pH in the gastrointestinal (Gl) tract, powerful digestive enzymes, and active agent impermeable gastrointestinal membranes. Among the numerous agents which are not typically amenable to oral administration are biologically active peptides, such as calcitonin and insulin; polysaccharides, and in particular mucopolysaccharides including, but not limited to, heparin; heparinoids; antibiotics; and other organic substances. These agents are rapidly rendered ineffective or are destroyed in the gastrointestinal tract by acid hydrolysis, enzymes, or the like.
  • However, broad spectrum use of drug delivery systems is often precluded because: (1) the systems require toxic amounts of adjuvants or inhibitors; (2) suitable low molecular weight active agents are not available; (3) the systems exhibit poor stability and inadequate shelf life; (4) the systems are difficult to manufacture; (5) the systems fail to protect the active agent; (6) the systems adversely alter the active agent; or (7) the systems fail to allow or promote absorption of the active agent.
  • There is still a need in the art for simple, inexpensive delivery systems which are easily prepared and which can deliver a broad range of active agents. One class of delivery system that has shown promise as excipients is diketopiperazines (DKP). In particular, 3,6-bis-substituted-2,5-diketopiperazines have been shown to effectively deliver biologically active agents across the lining of the lung.
  • Conventional synthesis of diketopiperazines proceeds via a cyclocondensation of two amino acid molecules or a dipeptide. One exemplary process for the synthesis of diketopiperazines, entails heating an amino acid (Cbz-L-lysine for example) in m-cresol for between 17 and 22 hours at 160-170ºC, and recrystallizing the diketopiperazine from acetic acid for a yield of about 48%.
  • US Patent No. 7,709,639 to Stevenson et. al. details methods for the synthesis of bis-Cbz-N-protected diketopiperazines, the disclosure of which is hereby incorporated by reference in its entirety as if recited fully herein.
  • Others have generated diketopiperazines from isolated dipetides by heating in an appropriate solvent while removing water by distillation. While these provide the desired diketopiperazines, the methods provide suboptimal yields and may require prolonged purification. Thus, there is a need for an improved method for the synthesis of disubstituted 2,5-diketopiperazines that provides the N-protected diketopiperazines in good yield while preserving the protecting groups and requiring minimal purification.
  • SUMMARY
  • This and other unmet needs of the prior art are met by compounds and methods as described in more detail below. The use of N-substituted 3,6-aminoalkyl-2,5-diketopiperazines as pharmaceutical excipients has shown considerable promise. As noted above, these compounds are often synthesized via cyclocondensation of amino acids. If the amino acid has a free nitrogen on its side-chain (as in, for example, lysine or ornithine) it is often necessary to have this nitrogen blocked prior to the cyclization reaction. Because of the potential for disparate synthetic processes after cyclization, compatibility with a variety of protecting groups is desired. Thus a synthetic method that can accommodate a number of diverse N-protecting groups and produce good yield of N-protected diketopiperazine is desired.
  • Some useful protecting groups include trifluoroacteyl, acetyl and other amide forming protecting groups; carbamate protecting groups including benzyloxycarbonyl (Cbz) and t-butoxycarbonyl (BOC).
  • In an embodiment, 3,6-bis-4-(N-trifluoroacetyl)aminobutyl-2,5-diketopiperazine is formed by heating ε-trifluoroacetyl-L-lysine in a water miscible solvent such as N-methyl-2-pyrrolidone (NMP) in the presence of a catalyst chosen from the group comprising phosphoric acid, sulfuric acid and phosphorous pentoxide to a temperature of about 150-175ºC. The diketopiperazine is isolated by quenching with water and filtering the resulting solid.
    Figure imgb0001
  • Disclosed embodiments describe methods for the synthesis of 3,6-bis-[N-protected aminoalkyl]-2,5-diketopiperazine comprising heating a mixture of an amino acid of general formula I in the presence of a catalyst in an organic solvent; wherein the catalyst is selected from the group comprising sulfuric acid, phosphoric acid, p-toluenesulfonic acid, 1-propylphosphonic acid cyclic anhydride, tributyl phosphate, phenyl phosphonic acid and phosphorous pentoxide among others; and wherein the solvent is selected from the group comprising: dimethylacetamide, N-methyl-2-pyrrolidone, diglyme, ethyl glyme, proglyme, ethyldiglyme, m-cresol, p-cresol, o-cresol, xylenes, ethylene glycol and phenol among others.
  • The disclosed embodiments also describe methods wherein n is equal to 3, wherein n is equal to 2, wherein PG is an amide forming protecting group, wherein the protecting group is trifluoroacetyl, wherein PG is a carbamate forming protecting group, wherein the protecting group is Cbz, wherein the solvent is substantially water miscible, wherein the solvent is N-methyl-2-pyrrolidone, wherein the amino acid is ε-trifluoroacetyl-L-lysine, wherein the amino acid is ε-Cbz-L-lysine, wherein the amino acid is γ-trifluoroacetyl-ornithine, wherein the amino acid is γ-Cbz-ornithine, wherein the catalyst is phosphorous pentoxide, wherein the concentration of phosphorous pentoxide is from 10% to about 50% that of the amino acid, and embodiments further comprising the step of quenching the mixture with water.
  • Disclosed embodiments describe methods for the synthesis of 3,6-bis-[N-protected aminobutyl]-2,5-diketopiperazine comprising: heating a mixture of a N-protected lysine in the presence of a catalyst in an organic solvent, to a temperature of between 110º and 175ºC for between 0.25 and 5 hours; wherein the catalyst is selected from the group comprising sulfuric acid, phosphoric acid and phosphorous pentoxide, the concentration of catalyst from about 5% to about 50% that of the lysine; and the solvent is selected from the group comprising: dimethylacetamide, N-methyl-2-pyrrolidone, diglyme, ethyl glyme, proglyme, ethyldiglyme, m-cresol, p-cresol, o-cresol, xylenes, ethylene glycol and phenol.
  • Disclosed embodiments describe methods for the synthesis of 3,6-bis-4-(N-trifluoroacetyl)aminobutyl-2,5-diketopiperazine comprising: heating a mixture of ε-trifluoroacetyl-L-lysine in the presence of phosphorous pentoxide in N-methyl-2-pyrrolidone, to a temperature of between 150º and 175ºC for between 0.25 and 5 hours, the concentration of phosphorous pentoxide is from about 10% to about 40% that of the lysine; and quenching the mixture with a second solvent, or alternatively, wherein the concentration of phosphorous pentoxide to lysine is between 20% and 35% and the mixture is quenched with water.
  • Any combination of the above described elements in all possible variations thereof is encompassed by the disclosed embodiments unless otherwise indicated herein or otherwise clearly contradicted by context.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • A better understanding of the exemplary embodiments of the invention will be had when reference is made to the accompanying drawings, wherein identical parts are identified with identical reference numerals, and wherein:
    • FIGURE 1 is a scheme showing the cyclocondensation of an N-protected amino acid into a diketopiperazine.
    • FIGURE 2 is a scheme showing the cyclocondensation of ε-trifluoroacetyl lysine.
    • FIGURE 3 is a scheme showing the cyclocoondensation of γ-Cbz-ornithine.
    DETAILED DESCRIPTION
  • As used herein, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl and all bond isomers are to be considered as alkyl. These can be mono- or poly-substituted with (C1-C8)-alkoxy, (C1 - C8)-haloalkyl, OH, halogen, NH2, NO2, SH, S-(C1 -C8) alkyl. (C2-C8)-alkenyl, with the exception of methyl, is understood to mean a (C1-C8)-alkyl group as illustrated above having at least one double bond.
  • A side-chain group of an α-amino acid is understood to mean the changeable group on the α-C atom of glycine as the basic amino acid. Natural amino acids are given for example in Bayer-Walter, Lehrbuch der organischen Chemie, S. Hirzel Verlag, Stuttgart, 22nd edition, page 822ff. Preferred synthetic amino acids and protected amino acids are available from the Sigma -Aldrich Company. The side chain groups can be derived from those referred to there.
  • The stated chemical structures relate to all possible stereoisomers that can be obtained by varying the configuration of the individual chiral centers, axes or surfaces, in other words all possible diastereomers as well as all optical isomers (enantiomers) falling within this group.
  • Turning to the drawings for a better understanding, FIGURE 1 shows a general scheme for the synthesis of a disubstituted diketopiperazine. This scheme shows an N-protected amino acid undergoing a cyclocondensation with a second amino acid molecule. In this embodiment, PG represents a protecting group for the nitrogen and n may be from 0 to 7. It is evident from the scheme that it is necessary when forming a diketopiperazine with an amine on a side chain that the nitrogen(s) must be blocked prior to the cyclization reaction or yields will be affected by unwanted side condensations. Depending on the chemistry that will be performed after ring formation, a variety of protecting groups are desired, and thus a method that accommodates many groups is preferred. Some useful protecting groups include trifluoroacteyl, acetyl and other amide forming protecting groups; carbamate protecting groups including benzyloxycarbonyl (Cbz) and t-butoxycarbonyl (BOC).
  • Known methods of cyclocondensation of amino acids to form DKP employed solvents such as n-butanol (water miscibility of about 7-8%), whereas solvents such as NMP are more miscible with water allowing a simple water quench/wash to remove reaction solvent and, if the catalyst has significant water solubility, the catalyst, all at once. In an embodiment, the catalyst for the amino acid cyclocondensation is water soluble allowing a water quench and subsequent removal by filtration.
  • Figure 2 illustrates an embodiment wherein PG is trifluoroacetyl and n is equal to 3. Thus, the starting amino acid is ε-trifluoroacetyl lysine and the product is 3,6-bis-4-(N-trifluoroacetyl)aminobutyl-2,5-diketopiperazine. An example of a method for the synthesis of 3,6-bis-4-(N-trifluoroacetyl)aminobutyl-2,5-diketopiperazine follows:
  • EXAMPLES AND REFERENCE EXAMPLES
  • Example 1 and 2
  • Figure imgb0002
  • To a 1 L, 3-neck round bottom flask equipped with a nitrogen purge, a distillation apparatus, a mechanical stirrer and a thermocouple with a temperature display, was added: NMP (256 mL), TFA-Lys (125 g, 0.52 mol) and P2O5 (22 g, 0.15 mol). The reaction mixture was heated to 160ºC and held there for 1.5 h. The mixture was then cooled to 100ºC and poured into DI water. The mixture was then cooled below 25ºC. and the solids were isolated via filtration, washed with DI water and dried in vacuo at 50ºC. to yield 3,6-bis-4-(N-trifluoroacetyl)aminobutyl-2,5-diketopiperazine (65.28g, 56.4%). 1H-NMR (DMSO-d6): 1.3 (m, 4H), 1.5 (m, 4H), 1.7 (m, 4H), 3.2 (q, 4H), 3.8 (m, 2H), 8.1 (s, 2H), 9.4 (s, 2H). Elemental analysis, calc'd C: 42.86; H: 4.95; N 12.50; F: 25.42. Found: C: 42.95; H: 4.91; N: 12.53; F: 24.99.
  • To a 100 gallon glass-lined reactor was added N-methyl-2-pyrollidone (200 L) and stirring was started. To the solvent was added TFA-lysine (100 kg, 413 mol) at ambient temperature. To the resulting slurry was added phosphorous pentoxide (15.2 kg, 107 mol). The mixture was then heated to 160ºC for 1 h. After 1 h at 160ºC the mixture was cooled to 100ºC and water (500 L) was added. The resulting mixture was cooled to 25ºC and held there for 90 minutes. The resulting solids were washed twice with water (265 L each) and isolated by filtration to give 3,6-bis-4-(N-trifluoroacetyl)aminobutyl-2,5-diketopiperazine in 50% yield.
  • A variety of catalysts were examined for the formation of bis-substituted diketopiperazines. The results of the catalyst survey are shown in Table 1. A general scheme and example for this survey follows:
  • Example 3
  • Figure imgb0003
  • Cbz-lysine (10.0 g), diethylene glycol dimethyl ether (diglyme; 50 mL), and a catalyst were charged to a 250 mL round bottom flask. The mixture was heated to 160 - 165 °C for 2.5 hours. The reaction mixture was poured into water and cooled to ambient temperature overnight. The precipitated solid was isolated by filtration, washed with water, and dried in vacuo at 50 °C. Table 1. Catalysts for diketopiperazine synthesis.
    Catalyst Amount Reaction yield
    P2O5 0.76 g (0.15 eq.) 55%
    P2O5 1.76 g (0.30 eq.) 45%
    H2SO4 1.27 mL (0.35 eq.) 55%
    H3PO4 0.73 mL (0.30 eq.) 65%
    p-toluene sulfonic acid 3.39 g (0.50 eq.) 52%
    1-propylphosphonic acid cyclic anhydride 4.54 g (0.20 eq.) 79%
    tributyl phosphate 2.44 g (0.30 eq.) 89%
    ethyl phosphonic acid 1.18 g (0.30 eq.) 0%
    phenyl phosphonic acid 1.13 g (0.20 eq.) 78%
  • Sulfuric acid and phosphorous pentoxide (at two concentrations) were surveyed further for synthesis of 3,6-bis-4-(N-trifluoroacetyl)aminobutyl-2,5-diketopiperazine in diglyme. The results are shown in Table 2.
  • Example 4
  • Figure imgb0004
  • TFA-lysine (10.0 g), diethylene glycol dimethyl ether (50 mL), and a catalyst were charged to a 250 mL round bottom flask. The mixture was heated to 160 - 165 °C for 2.5 hours. The reaction mixture was poured into water and cooled to ambient temperature. The precipitated solid was isolated by filtration, washed with water and dried in vacuo at 50 °C. Table 2. Catalysts for TFA-lysine diketopiperazine synthesis.
    Catalyst Amount Reaction yield
    P2O5 0.88 g (0.15 eq.) 41%
    P2O5 1.76 g (0.30 eq.) 55%
    H2SO4 0.8 mL (0.35 eq.) 40%
  • Sulfuric acid and phosphorous pentoxide (at two concentrations) were surveyed further for synthesis of 3,6-bis-4-(N-trifluoroacetyl)aminobutyl-2,5-diketopiperazine in dimethylacetamide (DMAc). The results are shown in Table 3.
  • Example 5
  • Figure imgb0005
  • TFA-lysine (25.0 g), dimethylacetamide (125 mL), and a catalyst were charged to a 250 mL round bottom flask. The mixture was heated to 160 - 165 °C for 2.5 hours. The reaction mixture was cooled to 100 °C, poured into water, and then cooled to ambient temperature. The precipitated solid was isolated by filtration, washed with water and dried in vacuo at 50 °C. The results are shown in Table 3. Table 3. Catalysts for TFA-lysine diketopiperazine synthesis.
    Catalyst Amount Reaction yield
    P2O5 2.2 g (0.15 eq.) 35%
    P2O5 5.13 g (0.35 eq.) 50%
    H2SO4 4.19 g (0.40 eq.) 16%
  • The use of phosphorous pentoxide was examined for the synthesis of 3,6-bis-4-(N-trifluoroacetyl)aminobutyl-2,5-diketopiperazine in N-methyl-2-pyrrolidone (NMP) at different times and temperatures. The results are shown in Table 4.
  • Example 6
  • Figure imgb0006
  • TFA-lysine (50 g), N-methyl pyrrolidone (125 mL), and P2O5 (8.8 g, 0.3 eq.) were charged to a round bottom flask. The mixture was heated to a reaction temperature for a reaction time. The reaction mixture was cooled, poured into water, and then cooled to ambient temperature. The precipitated solid was isolated by filtration, washed with water and dried in vacuo at 50 °C. Table 4. Reaction times and temperatures for TFA-lysine diketopiperazine synthesis.
    Reaction temp (°C) Reaction time Reaction yield
    110 0.25 19%
    110 5 54%
    170 0.25 59%
    170 5 42%
  • Example 7
  • Figure imgb0007
  • TFA-lysine (10.0 g), m-cresol (22 mL), and P2O5 were charged to a 250 mL round bottom flask. The mixture was heated to 160 - 165 °C for 1 hour. The reaction mixture was cooled to 65 °C, poured into a solution of 5% aqueous NaOH and methanol, and then cooled to ambient temperature. The precipitated solid was isolated by filtration, washed with water and dried in vacuo at 50 °C. Product yield was 12%.
  • Example 8
  • Figure imgb0008
  • TFA-lysine (50.0 g) and ethylene glycol (150 mL) were charged to a 500 mL round bottom flask. The mixture was heated to 160 - 170 °C for 2 hours. The reaction mixture was poured into water and cooled to ambient temperature. The precipitated solid was isolated by filtration, washed with water and dried in vacuo at 50 °C. Product yield was 2%.
  • Example 9
  • Figure imgb0009
  • Cbz-lysine (100.0 g) and ethylene glycol (300 mL) were charged to a 1000 mL round bottom flask. The mixture was heated to 160 - 170 °C for 6 hours. The reaction mixture was poured into a mixture of water and methanol and cooled to ambient temperature. The precipitated solid was isolated by filtration, washed with water and dried in vacuo at 50 °C. Product yield was 64%.
  • Figure 3 shows a general scheme for the cyclocondensation of γ-Cbz-ornithine.
  • Example 10
  • Figure imgb0010
  • CBz-ornithine (100 g), N-methyl pyrrolidone (194 mL), and P2O5 (8 g) were charged to a 1000 mL round bottom flask. The mixture was heated to 160 - 165 °C for 2 hours. The reaction mixture was poured into water and cooled to ambient temperature. The precipitated solid was isolated by filtration, washed with methanol and water, and dried in vacuo at 50 °C. The product yield was 51 %.
  • Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the disclosed embodiments. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the disclosed embodiments are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
  • The terms "a" and "an" and "the" and similar references used in the context of describing the disclosed embodiments (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
  • Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as") provided herein is intended merely to better illuminate the disclosed embodiments and does not pose a limitation on the scope of the disclosed embodiments unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the disclosed embodiments or any variants thereof.
  • Groupings of alternative elements or embodiments disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of any and all Markush groups used in the appended claims.
  • Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention(s). Of course, variations on the disclosed embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention(s) to be practiced otherwise than specifically described herein. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above described elements in all possible variations thereof is encompassed by the disclosed embodiments unless otherwise indicated herein or otherwise clearly contradicted by context.
  • Furthermore, references have been made to patents and printed publications throughout this specification.
  • Having shown and described an embodiment of the invention, those skilled in the art will realize that many variations and modifications may be made to affect the described invention and still be within the scope of the claimed invention. Additionally, many of the elements indicated above may be altered or replaced by different elements which will provide the same result.
  • It is the intention, therefore, to limit the invention only as indicated by the scope of the claims.

Claims (7)

  1. A method for the synthesis of 3,6-bis-[N-protected aminoalkyl]-2,5-diketopiperazine comprising:
    Figure imgb0011
    heating a mixture of an amino acid of general formula I in the presence of a catalyst in an organic solvent;
    wherein the catalyst is phosphorous pentoxide, wherein the concentration of phosphorous pentoxide to the amino acid is 20 mol % to 50 mol %;
    wherein n is 2 or 3;
    wherein the PG is trifluoroacetyl; and
    wherein the solvent is selected from the group consisting of:
    dimethylacetamide, N-methyl-2-pyrrolidone, diglyme, ethyl glyme, proglyme, ethyldiglyme.
  2. The method of claim 1 wherein the solvent is water miscible.
  3. The method of claim 1 wherein the solvent is N-methyl-2-pyrrolidone.
  4. The method of claim 1 wherein the amino acid is ε-trifluoroacetyl-L-lysine.
  5. The method of claim 1 wherein the amino acid is γ-trifluoroacetyl-ornithine.
  6. The method of claim 1 further comprising the step of quenching the mixture with water.
  7. A method according to claim 1 for the synthesis of 3,6-bis-4-(N-trifluoroacetyl)aminobutyl-2,5-diketopiperazine comprising:
    heating a mixture of ε-trifluoroacetyl-L-lysine in the presence of phosphorous pentoxide in N-methyl-2-pyrrolidone, to a temperature of between 150° and 175°C for between 0.25 and 5 hours, the concentration of phosphorous pentoxide is 20 mol % to 35 mol % that of the lysine; and
    quenching the mixture with water.
EP12744320.8A 2011-02-10 2012-02-07 Formation of n-protected bis-3,6-(4-aminoalkyl) -2,5,diketopiperazine Active EP2673265B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201161441525P true 2011-02-10 2011-02-10
PCT/US2012/024160 WO2012109256A2 (en) 2011-02-10 2012-02-07 Formation of n-protected bis-3,6-(4-aminoalkyl) -2,5,diketopiperazine

Publications (3)

Publication Number Publication Date
EP2673265A2 EP2673265A2 (en) 2013-12-18
EP2673265A4 EP2673265A4 (en) 2014-08-06
EP2673265B1 true EP2673265B1 (en) 2016-10-19

Family

ID=46639161

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12744320.8A Active EP2673265B1 (en) 2011-02-10 2012-02-07 Formation of n-protected bis-3,6-(4-aminoalkyl) -2,5,diketopiperazine

Country Status (13)

Country Link
US (4) US8912328B2 (en)
EP (1) EP2673265B1 (en)
JP (1) JP6018586B2 (en)
KR (1) KR20140027937A (en)
CN (2) CN103534242B (en)
AU (2) AU2012214592B2 (en)
BR (1) BR112013020514A2 (en)
CA (1) CA2826973A1 (en)
IL (1) IL227904A (en)
MX (1) MX346331B (en)
RU (1) RU2606624C2 (en)
SG (3) SG10201600967VA (en)
WO (1) WO2012109256A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
AU2005277208B2 (en) * 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
DK2322180T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for drug delivery
KR20120060245A (en) 2005-09-14 2012-06-11 맨카인드 코포레이션 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
JP5599975B2 (en) 2006-02-22 2014-10-01 マンカインド コーポレイション Method for improving the formulation properties of the fine particles containing diketopiperazine and an active agent
DK2570147T3 (en) 2008-06-13 2018-01-29 Mannkind Corp Dry powder inhaler and system for drug administration
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
RU2470681C2 (en) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Interactive system and method for real-time force profiling in inhalation
TWI614024B (en) 2008-08-11 2018-02-11 Mannkind Corp Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (en) 2009-03-11 2013-12-16 Mannkind Corp An apparatus, system and method for measuring resistance in an inhaler
KR20190090092A (en) 2009-06-12 2019-07-31 맨카인드 코포레이션 Diketopiperazine microparticles with defined specific surface areas
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
CN104284918B (en) * 2012-03-28 2017-03-29 高剑萍 Ester type urethane and urea type compounds and methods
JP6241682B2 (en) 2012-04-27 2017-12-06 マンカインド・コーポレイシヨン Its use as a method and intermediates for the synthesis of activated ethyl fumarate
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
SG11201507132UA (en) * 2013-03-15 2015-10-29 Mannkind Corp Formation of n-protected bis-3,6-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-n-protected amino ester
CA2918369A1 (en) 2013-07-18 2015-01-22 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105254576A (en) * 2014-02-26 2016-01-20 中国科学院长春应用化学研究所 Method for preparing glutamic piperazinedione
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2017025031A1 (en) * 2015-08-10 2017-02-16 于跃 Diazaoxa heterocyclic spiro-dione piperazine alkaloid derivative having antiviral activity and preparation method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
JPH06321916A (en) * 1993-05-14 1994-11-22 Mitsui Toatsu Chem Inc Production of 3,6-bis((4-hydroxyphenyl)methyl)-2,5-diketopiperazine
JP2001511810A (en) * 1997-02-13 2001-08-14 モンサント カンパニー Method for producing amino acids
US6337678B1 (en) * 1999-07-21 2002-01-08 Tactiva Incorporated Force feedback computer input and output device with coordinated haptic elements
US6590993B2 (en) * 1999-09-06 2003-07-08 Koninklijke Philips Electronics N.V. Panel-shaped loudspeaker
DE10019879A1 (en) 2000-04-20 2001-10-25 Degussa Production of known and new 2,5-diketopiperazine derivatives useful for the synthesis of bioactive compounds, e.g. cyclo(Lys-Lys)
AU2005277208B2 (en) * 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
JP4968848B2 (en) * 2008-01-30 2012-07-04 株式会社Adeka Polyolefin resin composition
CN101851213A (en) * 2010-06-21 2010-10-06 于清 Synthetic methods of 3,6-bis(4-bisfumaroyl aminobutyl)-2,5-diketopiperazine and salt substitute thereof
CN101914032B (en) * 2010-07-15 2013-06-05 启东市沪东化工有限公司 Synthetic method of (s)-N-trifluoroacetyl-2-(4-Methoxyphenyl)ethylamine

Also Published As

Publication number Publication date
IL227904D0 (en) 2013-09-30
CN103534242B (en) 2016-04-20
CA2826973A1 (en) 2012-08-16
RU2013138609A (en) 2015-03-20
RU2606624C2 (en) 2017-01-10
JP2014513045A (en) 2014-05-29
AU2012214592B2 (en) 2017-03-09
AU2012214592A1 (en) 2013-08-29
CN103534242A (en) 2014-01-22
MX2013009260A (en) 2014-08-21
US20150073149A1 (en) 2015-03-12
WO2012109256A3 (en) 2013-01-24
US8912328B2 (en) 2014-12-16
SG10201802008TA (en) 2018-04-27
WO2012109256A2 (en) 2012-08-16
US10196366B2 (en) 2019-02-05
EP2673265A2 (en) 2013-12-18
US20130012710A1 (en) 2013-01-10
KR20140027937A (en) 2014-03-07
CN105884700A (en) 2016-08-24
JP6018586B2 (en) 2016-11-02
US20190169135A1 (en) 2019-06-06
MX346331B (en) 2017-03-15
SG10201600967VA (en) 2016-03-30
EP2673265A4 (en) 2014-08-06
IL227904A (en) 2016-12-29
US9416113B2 (en) 2016-08-16
US20160347721A1 (en) 2016-12-01
BR112013020514A2 (en) 2016-07-12
AU2017203860A1 (en) 2017-06-22
SG192708A1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
Ozaki et al. 5-Fluorouracil derivatives. I. The synthesis of 1-carbamoyl-5-fluorouracils
CA2377278C (en) Prodrugs of carbamate inhibitors of impdh
CA2526007C (en) Releasable polymeric conjugates based on aliphatic biodegradable linkers
EP1948242B1 (en) Cytotoxic compounds
ES2241581T3 (en) dimer compounds and their use as neuraminidase inhibitors.
KR100352048B1 (en) Stilbene derivatives and pharmaceutical compositions containing them
US3407203A (en) Novel process for the preparation of diketopiperazines
US6967202B2 (en) Method of synthesizing diketopiperazines
AU655798B2 (en) 2,4-diaminoquinazolines derivatives for enhancing antitumor activity
AU2002346296B2 (en) Block copolymer reduced in impurity content, polymeric carrier, pharmaceutical preparations in polymeric form and process for the preparation of the same
JP4177484B2 (en) Substituted diamino carboxylic acids
US5840900A (en) High molecular weight polymer-based prodrugs
Chakravarty et al. Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin
US6127355A (en) High molecular weight polymer-based prodrugs
CN1164573C (en) Novel alpha-amino acid compound, its preparation process and medicinal composition containing same
AU2004281536B2 (en) Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases
US6559314B2 (en) Method for the production of thiazolidin
ES2385934T3 (en) Catalyzing the synthesis of diketopiperazine.
Drewry et al. Solid-phase synthesis of trisubstituted guanidines
KR20010023449A (en) Novel cyclic tetrapeptide derivatives and medicinal use thereof
NL8100391A (en) Agmatinederivaten, process for the preparation thereof, and pharmaceutical preparations based on the new agmatinederivaten.
Famulok et al. Formation of N‐(Deoxyguanosin‐8‐yl) aniline in the in vitro Reaction of N‐Acetoxyaniline with Deoxyguanosine and DNA
JP2540534B2 (en) Oligo peptidyl nitrile derivatives
Gallou Unsymmetrical ureas. Synthetic methodologies and application in drug design
CA2431487C (en) Oligo or polyalkylene glycol-coupled thrombin inhibitors

Legal Events

Date Code Title Description
AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

17P Request for examination filed

Effective date: 20130903

DAX Request for extension of the european patent (to any country) (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140707

RIC1 Information provided on ipc code assigned before grant

Ipc: B01J 31/02 20060101ALI20140701BHEP

Ipc: C07D 241/08 20060101AFI20140701BHEP

Ipc: C07C 229/00 20060101ALI20140701BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192883

Country of ref document: HK

17Q First examination report despatched

Effective date: 20151009

RAP1 Rights of an application transferred

Owner name: MANNKIND CORPORATION

INTG Intention to grant announced

Effective date: 20160502

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 838195

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012024339

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20161019

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 838195

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170120

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170219

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170220

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012024339

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170119

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012024339

Country of ref document: DE

26N No opposition filed

Effective date: 20170720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20170207

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161019

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20171031

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: DE

Ref legal event code: R073

Ref document number: 602012024339

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170207

REG Reference to a national code

Ref country code: GB

Ref legal event code: S28

Free format text: APPLICATION FILED

REG Reference to a national code

Ref country code: DE

Ref legal event code: R074

Ref document number: 602012024339

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170228

REG Reference to a national code

Ref country code: FR

Ref legal event code: RN

Effective date: 20171226

REG Reference to a national code

Ref country code: GB

Ref legal event code: S28

Free format text: RESTORATION ALLOWED

Effective date: 20180123

REG Reference to a national code

Ref country code: FR

Ref legal event code: FC

Effective date: 20180116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170207

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170228

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: FR

Effective date: 20180116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170207

PGFP Annual fee paid to national office [announced from national office to epo]

Ref country code: GB

Payment date: 20190218

Year of fee payment: 8

Ref country code: DE

Payment date: 20190219

Year of fee payment: 8

Ref country code: CH

Payment date: 20190218

Year of fee payment: 8

PGFP Annual fee paid to national office [announced from national office to epo]

Ref country code: FR

Payment date: 20190220

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120207